文献速递造血干细胞移植与细胞治疗血栓与止血

芦可替尼治疗异基因造血细胞移植后闭塞性细支气管炎综合征的多中心2期试验

A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.
PubMed 文献 · Blood Adv · 2025-01-01

这项前瞻性多中心2期试验纳入49例异基因造血细胞移植后闭塞性细支气管炎综合征(BOS)成人患者,接受芦可替尼10 mg每日两次、28天周期连续用药最多12周期;新诊断组(A组,n=36)3个月FEV1改善达标率27.8%,已确立组(B组,n=13)稳定达标率92.3%,2014年NIH共识标准下最佳肺部总体缓解率34.7%。

要点

  • 芦可替尼10 mg每日两次、28天周期连续用药最多12周期治疗移植后BOS。
  • A组3个月FEV1改善(≥10%增加)达标率27.8%,B组稳定(无≥10%下降)达标率92.3%。
  • 49例最佳肺部总体缓解率34.7%(完全缓解16.3%、部分缓解18.4%),多见于轻中度疾病。

核心结论

  • 这些结果支持芦可替尼用于异基因造血细胞移植后BOS的管理。

研究设计与样本

  • 前瞻性、多中心2期试验,纳入49例符合BOS标准的成人患者,A组为新诊断(BOS诊断<6个月)36例,B组为已确立(BOS诊断≥6个月)13例。
  • 芦可替尼10 mg每日两次,28天周期连续用药,最多12周期。
  • 主要目的为评估早期疗效,以入组时相比3个月时第1秒用力呼气容积(FEV1)变化评定;主要终点按队列不同:A组为改善(FEV1增加≥10%),B组为稳定(FEV1无≥10%下降)。

主要发现

  • 主要终点达标率:A组27.8%,B组92.3%。
  • 按2014年美国国立卫生研究院(NIH)共识标准,49例最佳肺部总体缓解率为34.7%,其中完全缓解16.3%、部分缓解18.4%,多数缓解见于轻或中度疾病。
  • 非感染性严重(≥3级)治疗中出现的不良事件不常见;发生9例严重感染事件,多为呼吸道性质。

关键数值与推荐

  • 主要终点按队列定义:A组FEV1较入组时增加≥10%为改善,B组FEV1无≥10%下降为稳定。
  • 疗效评估采用2014年NIH共识标准。

临床怎么用

  • 作者认为这些结果支持芦可替尼用于异基因造血细胞移植后BOS的管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bronchiolitis obliterans syndrome (BOS) occurring after allogeneic hematopoietic cell transplantation (HCT) is a high-risk manifestation of chronic graft-versus-host disease. In this prospective, multicenter phase 2 trial, adult participants with BOS were treated with ruxolitinib 10 mg twice daily, continuously in 28-day cycles for up to 12 cycles. Participants enrolled into newly diagnosed (<6 months since BOS diagnosis, cohort A) or established (≥6 months since BOS diagnosis, cohort B) disease cohorts. The primary objective was to evaluate the early treatment effect of ruxolitinib, assessed by the change in forced expiratory volume in 1 second (FEV1) at 3 months compared with enrollment. The primary end point differed according to cohort (cohort A, improvement, defined as ≥10% increase in FEV1; cohort B, stabilization, defined as an absence of ≥10% decrease in FEV1). Between 2019 and 2022, 49 participants meeting the criteria for BOS were enrolled and treated (cohort A, n = 36; cohort B, n = 13). The primary end point was achieved by 27.8% of participants with new BOS and 92.3% of participants with established BOS. According to the 2014 National Institutes of Health Consensus Criteria, the best lung-specific overall response rate on ruxoltinib for the 49 participants was 34.7% (16.3% complete response and 18.4% partial response), with most responses occurring in mild or moderate disease. Noninfectious severe (grade ≥3) treatment-emergent adverse events were infrequent. Nine severe infectious events occurred and were largely respiratory in nature. These results support the use of ruxolitinib in the management of BOS after allogeneic HCT. This trial was registered at www.ClinicalTrials.gov as #NCT03674047.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DeFilipp Z, Kim HT, Cheng GS, et al. A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT. Blood Adv. 2025. PMID: 39365992. doi:10.1182/bloodadvances.2024014000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。